{
  "main_header": {
    "sid": 225982,
    "name": "Venmax Drugs",
    "stock_name": "Venmax Drugs",
    "full_name": "Venmax Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/venmax-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "24.65",
    "chg": 1.09,
    "chgp": "4.63%",
    "dir": 1,
    "prev_price": "23.56",
    "mcapval": "22.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531015,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE154G01022",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "1.84 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/venmax-drugs-225982-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Venmax Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-venmax-drugs-3695032",
        "imagepath": "",
        "date": "2025-11-13 00:04:45",
        "description": "Answer:\nThe historical performance of Venmax Drugs shows significant fluctuations in its financial metrics over the years, particularly in net sales, operating profit, and overall profitability.\n\nBreakdown:\nVenmax Drugs reported net sales of 0.81 Cr in March 2025, a notable increase from 0.00 Cr in March 2024, but still below the 2.55 Cr recorded in March 2015. The total operating income followed a similar trend, reaching 0.81 Cr in March 2025, compared to 0.00 Cr in the previous year. However, total expenditure surged to 1.86 Cr in March 2025, up from 0.10 Cr in March 2024, leading to an operating profit (PBDIT) of 0.00 Cr in March 2025, a decline from 0.10 Cr in March 2024. The profit before tax was slightly negative at -0.01 Cr in March 2025, contrasting with a profit of 0.09 Cr in March 2024. Consequently, the profit after tax also fell to -0.01 Cr in March 2025 from 0.06 Cr in March 2024. The company's..."
      }
    ],
    "total": 73,
    "sid": "225982",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/venmax-drugs-pharmaceuticals-225982"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Unaudited Financial Results Of The Company For The Quarter Ended December 31 2025.",
      "datetime": "30-Jan-2026",
      "details": "Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve Unaudited Financial Results Of The Company For The Quarter Ended December 31 2025.",
      "source": "BSE"
    },
    {
      "caption": "Conversion Of Share Warrants Into Equity",
      "datetime": "21-Jan-2026",
      "details": "The Board of directors at its meeting held today i.e. January 21 2026 has approved the conversion of 775000 share warrants in to Equity.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "12-Jan-2026",
      "details": "Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended December 31 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Venmax Drugs?

2025-11-13 00:04:45

Answer: The historical performance of Venmax Drugs shows significant fluctuations in its financial metrics over the years, particularly in net sales, operating profit, and overall profitability. Breakdown: Venmax Drugs reported net sales of 0.81 Cr in March 2025, a notable increase from 0.00 Cr in March 2024, but still below the 2.55 Cr recorded in March 2015. The total operating income followed a similar trend, reaching 0.81 Cr in March 2025, compared to 0.00 Cr in the previous year. However, total expenditure surged to 1.86 Cr in March 2025, up from 0.10 Cr in March 2024, leading to an operating profit (PBDIT) of 0.00 Cr in March 2025, a decline from 0.10 Cr in March 2024. The profit before tax was slightly negative at -0.01 Cr in March 2025, contrasting with a profit of 0.09 Cr in March 2024. Consequently, the profit after tax also fell to -0.01 Cr in March 2025 from 0.06 Cr in March 2024. The company's...

Read More

View All News